

Performance in Delivering Clinical Research

1st October 2016 - 30th September 2017

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed
23234	15/EE/0464	183877	CRIT 4440 - A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients with Catecholamine-Resistant Hypotension (CRH)	Number Agreed	1	1
23235	15/WA/0241	183747	A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type 1 Diabetes Mellitus - Study Two	Number Agreed	6	6
23236	16/NE/0027	187317	A phase 3, multicenter, randomized, open-label study of avelumab (msb0010718c) alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer	Number Agreed	4	4
23237	15/LO/0545	172357	CARAT - RTSY03 - Clinical and device functional assessment of real world ICD patients	Number Agreed	6	6

Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
Date Agreed	30/06/2016	1	01/12/2016	1	Recruitment Finished	
Date Agreed	31/12/2016	10	26/11/2016	10	Recruitment Finished	
Date Agreed	01/06/2018	6	20/04/2017	6	Recruitment Finished	
Date Agreed	01/05/2017	7	01/05/2017	7	Recruitment Finished	